Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis

Journal of Infectious Diseases

Volumn 213, Issue 9, 2016, Pages 1444-1454

  Beachler, Daniel C ^a   Jenkins, Gwendolyne ^a   Safaeian, Mahboobeh ^a   Kreimer, Aimée R ^a   Wentzensen, Nicolas ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

antibodies; cervix; human papillomavirus; natural immunity; serology

Indexed keywords

VIRUS ANTIBODY; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 6; INFECTION RISK; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RISK FACTOR; SERODIAGNOSIS; SEX RATIO; SYSTEMATIC REVIEW; VIRUS IDENTIFICATION; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; VIRUS STRAIN; ADOLESCENT; ADULT; BLOOD; FEMALE; IMMUNOLOGY; MALE; META ANALYSIS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; YOUNG ADULT;

ADAPTIVE IMMUNITY; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; YOUNG ADULT;

EID: 84971616793     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv753     Document Type: Article

References (49)

1. Baseman JG, Koutsky LA. the epidemiology of human papillomavirus infections. J Clin Virol 2005; 32(suppl 1):S16-24.
2. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370:890-907.
3. Ho GYF. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423-8.
4. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007; 90:1-636.
5. Rodriguez AC, Schiffman M, Herrero R, et al. Low risk of type-specific carcinogenic HPV re-appearance with subsequent cervical intraepithelial neoplasia grade 2/3. Int J Cancer 2012; 131:1874-81.
6. Castellsague X, Naud P, Chow SN, et al. Risk of newly detected infections and cervical abnormalities in women seropositive for naturally-acquired HPV-16/18 antibodies: analysis of the control arm of PATRICIA. J Infect Dis 2014; 210:517-34.
7. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181:1911-9.
8. Tong Y, Ermel A, Tu W, Shew M, Brown D. Association of HPV types 6, 11, 16, and 18 DNA detection and serological response in unvaccinated adolescent women. J Med Virol 2013; 85:1786-93.
9. Coseo SE, Porras C, Dodd LE, et al. Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure. Sex Transm Dis 2011; 38:976-82.
10. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008; 26(suppl 10):K1-16.
11. Safaeian M, Porras C, Schiffman M, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and-18 infections. J Natl Cancer Inst 2010; 102:1653-62.
12. Franceschi S, Baussano I. Naturally-acquired immunity against HPV: why it matters in the HPV vaccine era. J Infect Dis 2014; 210:507-9.
13. Schiller JT, Lowy DR. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol 2012; 10:681-92.
14. Wilson L, Pawlita M, Castle PE, et al. Seroprevalence of eight oncogenic human papillomaviruses and acquired immunity against re-infection. J Infect Dis 2014; 210:448-55.
15. Wentzensen N, Rodriguez AC, Viscidi R, et al. A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study. J Infect Dis 2011; 204:94-102.
16. Viscidi RP, Schiffman M, Hildesheim A, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004; 13:324-7.
17. Viscidi RP, Snyder B, Cu-Uvin S, et al. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev 2005; 14:283-8.
18. Velicer C, Zhu X, Vuocolo S, Liaw KL, Saah A. Prevalence and incidence of HPV genital infection in women. Sex Transm Dis 2009; 36:696-703.
19. Malik ZA, Hailpern SM, Burk RD. Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV. Viral Immunol 2009; 22:445-9.
20. Mooij SH, Landen O, van der Klis FR, et al. No evidence for a protective effect of naturally induced HPV antibodies on subsequent anogenital HPV infection in HIV-negative and HIV-infected MSM. J Infect 2014; 69:375-86.
21. Lu B, Viscidi RP,Wu Y, et al. Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. Cancer Res 2012; 72:676-85.
22. Lu B, Hagensee ME, Lee JH, et al. Epidemiologic factors associated with seropositivity to human papillomavirus type 16 and 18 virus-like particles and risk of subsequent infection in men. Cancer Epidemiol Biomarkers Prev 2010; 19:OF1-6.
23. Robbins HA, Li Y, Porras C, et al. Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus. BMC Infect Dis 2014; 14:120.
24. Lin SW, Ghosh A, Porras C, et al. HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. PLoS One 2013; 8:e53067.
25. Ho GY, Studentsov Y, Hall CB, et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 2002; 186:737-42.
26. Beachler DC, Viscidi R, Sugar EA, et al. A longitudinal study of human papillomavirus 16 L1, E6, and E7 seropositivity and oral human papillomavirus 16 infection. Sex Transm Dis 2015; 42:93-7.
27. Dias D, Van Doren J, Schlottmann S, et al. Optimization and validation of a multiplexed Luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 2005; 12:959-69.
28. Harris RJ, Bradburn MJ, Deeks JJ, Harbord DG, Altman DG, Sterne JA. Metan: fixed-and random-effects meta-analysis. Stata J 2008; 8:3-28.
29. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14:467-75.
30. Alemany L, Saunier M, Alvarado-Cabrero I, et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer 2015; 136:98-107.
31. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. 2011. www.cochrane-handbook.org. Accessed 1 September 2015.
32. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-34.
33. Begg CB, Berlin JA. Publication bias: A problem in interpreting medical data. J R Stat Soc Ser A 1988; 151:419-63.
34. Sterne JA. Meta-analysis in Stata: an updated collection from the Stata Journal. College Station, TX: Stata Press, 2009.
35. Giuliano AR, Viscidi RP, Torres BN, et al. Seroconversion following anal and genital HPV infection in men: The HIM study. Papillomavirus Res 2015;1:109-15.
36. Szarewski A, Poppe WA, Skinner SR, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer 2012; 131:106-16.
37. Beachler DC, Kreimer AR, Schiffman M, et al. Multi-site HPV16/18 vaccine efficacy against cervical, anal, and oral HPV infection. J Natl Cancer Inst 2015; doi:10.1093/jnci/djv302.
38. Safaeian M, Porras C, Pan Y, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 2013; 6:1242-50.
39. Gravitt PE. Evidence and impact of human papillomavirus latency. Open Virol J 2012; 6:198-203.
40. Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR. Prevalence of HPV infection among men: A systematic review of the literature. J Infect Dis 2006; 194:1044-57.
41. Stone KM, Karem KL, Sternberg MR, et al. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 2002; 186:1396-402.
42. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29: 4294-301.
43. Shiels MS, Kreimer AR, Coghill AE, Darragh TM, Devesa SS. Anal cancer incidence in the United States, 1977-2011: distinct patterns by histology and behavior. Cancer Epidemiol Biomarkers Prev 2015; 24:1548-56.
44. Winer RL, Feng Q, Hughes JP, O'Reilly S, Kiviat NB, Koutsky LA. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 2008; 197:279-82.
45. Hariri S, Unger ER, Sternberg M, et al. Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006. J Infect Dis 2011; 204:566-73.
46. Giuliano AR, Lee JH, FulpW, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): A cohort study. Lancet 2011; 377:932-40.
47. Kim JJ, Ortendahl J, Goldie SJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med 2009; 151:538-45.
48. Chandra A, Mosher WD, Copen C, Sionean C. Sexual behavior, sexual attraction, and sexual identity in the United States: data from the 2006-2008 National Survey of Family Growth. Natl Health Stat Report 2011:1-36.
49. Herrero R. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Infect Dis 2009; 199:919-22.